A retrospective, real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 22 May 2020 New trial record
- 15 May 2020 Results published in the Investigational New Drugs